By the end of the 2000s, large research programs were mapping the genomic changes that drive cancer. The scientific founders of Foundation Medicine, including Eric Lander, Todd Golub, Levi Garraway, and Matthew Meyerson, helped lead that work across the Broad Institute and major cancer centers. The emerging premise was powerful: tumors that looked similar under a microscope could be driven by different molecular alterations and might respond to different therapies.
But discovery inside a research institution is not the same as a product that works in routine oncology. A community oncologist could not simply receive a tumor sequence and act. The sample had to be processed reliably. Relevant alterations had to be separated from noise. The result had to be connected to approved treatments, investigational therapies, and clinical trials. The information then had to arrive in a form that supported a real decision.
Foundation Medicine was created in 2010 around that translation problem. Its founders did not need to prove that cancer genomics existed. They needed to build an end-to-end clinical system around it.
The product was interpretation
The company’s first widely available product, FoundationOne, used next-generation sequencing to examine hundreds of cancer-related genes. Yet the sequencing panel alone was not the complete product. The clinical report, the evidence linking alterations to potential actions, the laboratory validation, the accumulating knowledge base, and the relationships with biopharmaceutical companies all made the information more useful.
This created two connected businesses. Clinical testing could help physicians and patients consider therapies and trials. The growing molecular database and testing platform could also support drug development and companion diagnostics. Each side strengthened the other, although adoption, reimbursement, and clinical interpretation remained difficult.
The company’s 2014 annual report showed both traction and unfinished work. Revenue had grown to $61.1 million, more than double the prior year, and the company reported more than 24,000 clinical tests. It also warned that wider use depended on physician adoption, reimbursement, and continued biopharmaceutical relationships. Scientific relevance did not remove the need to change clinical and payment systems.
In 2017, the FDA approved FoundationOne CDx as a broad companion diagnostic and genomic profiling test for solid tumors. Roche, which had taken a controlling interest in 2015, acquired the remaining shares in 2018. Those milestones validated parts of the platform, but they should not make the outcome look inevitable. The company had spent years converting a research capability into a validated laboratory process, an interpretable report, a regulatory product, and a business serving multiple stakeholders.
Foundation Medicine illustrates a form of innovation that is easy to underestimate. The breakthrough was not merely seeing more biological information. It was designing the layers that allowed information to travel from a tumor sample into a consequential decision.
Sources and further reading
Keep exploring
Flatiron Health: When do clinical records become research evidence?GRAIL: What must happen after a cancer signal?Put the question to work with an AI prompt →Browse all cases →For a discussion tailored to your team, explore a workshop with Julien.